Open Access Repository

Bertilimumab (Cambridge Antibody Technology Group)


Downloads per month over past year

Ding, C, Li, J and Zhang, X (2004) Bertilimumab (Cambridge Antibody Technology Group). Current Opinion in Investigational Drugs, 5 (11). pp. 1213-1219. ISSN 1472-4472

[img] PDF
bertilimumab.pdf | Request a copy
Full text restricted
Available under University of Tasmania Standard License.


Cambridge Antibody Technology (CAT) is developing
bertilimumab, an anti-eotaxin-1 monoclonal antibody, for the potential treatment of allergic disorders. By September 2003, CAT had released results from phase I/II trials, and was seeking to outlicense rights for bertilimumab.

Item Type: Article
Authors/Creators:Ding, C and Li, J and Zhang, X
Journal or Publication Title: Current Opinion in Investigational Drugs
Page Range: pp. 1213-1219
ISSN: 1472-4472
Date Deposited: 01 Apr 2008 03:00
Last Modified: 18 Nov 2014 03:32
Item Statistics: View statistics for this item

Actions (login required)

Item Control Page Item Control Page